Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.12.2022 | Case report

Antineoplastics/immunosuppressants

Cerebral toxoplasmosis and haematemesis: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Jondreville L, et al. FLAMSA-Busulfan-Melphalan as a Sequential Conditioning Regimen in HLA-Matched or Haploidentical Hematopoietic Stem Cell Transplantation for High-Risk Myeloid Diseases. Transplantation and Cellular Therapy 27: 915e1-915e8, No. 11, Nov 2021. Available from: URL: http://doi.org/10.1016/j.jtct.2021.07.018 Jondreville L, et al. FLAMSA-Busulfan-Melphalan as a Sequential Conditioning Regimen in HLA-Matched or Haploidentical Hematopoietic Stem Cell Transplantation for High-Risk Myeloid Diseases. Transplantation and Cellular Therapy 27: 915e1-915e8, No. 11, Nov 2021. Available from: URL: http://​doi.​org/​10.​1016/​j.​jtct.​2021.​07.​018
Metadaten
Titel
Antineoplastics/immunosuppressants
Cerebral toxoplasmosis and haematemesis: 2 case reports
Publikationsdatum
01.12.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-28877-1

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Dexamethasone

Case report

Apixaban

Case report

Antineoplastics

Case report

Tozinameran

Case report

Multiple drugs